Mesenchymal stem/stromal cells (MSCs) have a wide application in cell-based therapies and tissue engineering. In the present study, the differentiation, survivin (SVV)-modified effects and molecular basis of human umbilical cord-derived MSCs (HUMSCs) and dental pulp-derived stem cells (DPSCs) were investigated. The HUMSCs were found to differentiate into adipocytes more readily than the DPSCs and the HUMSCs and DPSCs were each able to differentiate into osteoblasts and chondroblasts. Following modification of the MSCs by SVV, the secretion of SVV in the modified HUMSCs was significantly higher compared with that in the modified DPSCs.

In vivo, survival of the SVV-modified DPSCs was observed at 4 and 14 days after intrastriatal transplantation, as was the expression of SVV and differentiation into astrocytes. The gene expression profiles of the control and modified HUMSCs and DPSCs were compared using RNA sequencing and an association was observed between gene expression and variability in cell line function. These findings provide novel information regarding the differences between HUMSCs and DPSCs and insight into optimal cell sources for therapeutic applications.

**Introduction**

Mesenchymal stem/stromal cells (MSCs) are able to extensively self-renew and possess a multilineage differentiation potential (1-3). In addition, MSCs exert a supportive function through paracrine effects (4-6). Therefore, these cells have a wide application in cell-based therapies and tissue engineering. Over the last decade, MSCs derived from alternative and easily accessible sources have received increasing attention. MSCs can be isolated from a large variety of fetal tissues, extraembryonic tissues and organs and a variety of tissues from children and adults (7).

Human umbilical cord-derived MSCs (HUMSCs) can be isolated and expanded easily in vitro without ethical concerns. Therefore, they have received interest as a promising candidate for several potential clinical applications (8) and several studies have demonstrated that HUMSCs exhibit this potential (9). HUMSCs may possess a capacity for autologous and allogenic transplantation due to their immunoprivileged properties (10). They are able to effectively suppress mitogen-induced T-cell proliferation (11) and low levels of rejection have been observed in animal transplantation studies (12,13).

Human umbilical cord-derived MSCs (HUMSCs) can be isolated and expanded easily *in vitro* without ethical concerns. Therefore, they have received interest as a promising candidate for several potential clinical applications (8) and several studies have demonstrated that HUMSCs exhibit this potential (9). HUMSCs may possess a capacity for autologous and allogenic transplantation due to their immunoprivileged properties (10). They are able to effectively suppress mitogen-induced T-cell proliferation (11) and low levels of rejection have been observed in animal transplantation studies (12,13).

HUMSCs and dental pulp-derived stem cells (DPSCs) offer available sources of autologous cells without ethical controversy. Human DPSCs were initially reported by Gronthos et al in 2000 and were observed to share a similar morphology and *in vitro* differentiation potential with bone marrow MSCs (14). DPSCs also possess immunoregulatory properties and are capable of inducing activated T-cell apoptosis *in vitro* and alleviating inflammatory-related tissue injury (15). Impacted adult wisdom teeth and naturally-exfoliated deciduous teeth do not ordinarily serve a function in adults. Therefore, DPSCs can be obtained without adverse effects on health.

HUMSCs are also amenable to genetic modification. Kermani et al (16) transfected HUMSCs with a green fluorescent protein (GFP)-reporter gene and established a stable cell line. There have been no reports on the genetic modification of DPSCs to date, to the best of our knowledge. Survivin (SVV), a 16.5 kDa protein, is a member of the X-linked inhibitor of apoptosis family and exhibits broadly cytoprotective
properties (17). In the present study, SVV-modified HUMSCs and DPSCs were investigated.

The potential clinical application of HUMSCs and DPSCs remains to be elucidated. In the present study, the differentiation, SVV-modified effects and molecular basis of the heterogeneity between HUMSCs and DPSCs were investigated in vitro and in vivo.

Materials and methods

Preparation of HUMSCs and DPSCs. HUMSCs were isolated, as previously described, with certain modifications (18). The human umbilical cords were obtained from babies delivered at full-term following institutional review board approval. A segment of umbilical cord, cut to ~7 cm in length was obtained. This segment was placed immediately into 25 ml complete medium, comprising Dulbecco's modified Eagle's medium (DMEM; HyClone, Shanghai, China) supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Grand Island, NY, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco Life Technologies). The tubes were stored on ice for dissection within 4 h. The umbilical cord segment was washed three times with phosphate-buffered saline (PBS) without calcium and magnesium (HyClone, Shanghai, China) and dissected longitudinally using an aseptic technique. The umbilical vein and the umbilical arteries were removed and the umbilical cord segment was cut into a 0.5-1 mm³ tissue block and incubated in 3 ml 0.2% collagenase type II (Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 37°C. A five-fold volume of complete medium was added and the supernatant was filtered using a 70-µm filter following free settling for 20 min. The cells were collected following centrifugation at 500 x g for 5 min and plated in plastic culture flasks at a concentration of 5x10⁵/cm². After 3 days, the non-adherent cells were removed by washing three times with PBS. The medium was changed every 2-3 days.

The human DPSCs were isolated as follows: Two adult wisdom teeth from one patient aged between 18 and 30 years old, which were extracted for clinical purposes at Tonji Hospital, were used. The root was isolated and digested in 0.3% collagenase I (Sigma-Aldrich) for 30 min at room temperature. The DPSCs were cultured in an incubator at 37°C and 5% CO₂. At 100% confluence, the medium was replaced with the adipogenic differentiation medium containing hydrocortisone, isobutylmethylxanthine, indomethacin in 95% ethanol and α minimum essential medium basal medium (R&D Systems, Inc). The medium was replaced every 3 days. After 2 weeks, the cells on the cover slips were washed with PBS twice and fixed with 4% paraformaldehyde (Beijing Solarbio Science & Technology, Beijing, China) for 20 min at room temperature. The cells were then washed with PBS and stained for 30 min using oil red O (Sigma-Aldrich). Following washing twice with PBS, images of cells were captured under a phase contrast microscope (IX71, Olympus Corp., Tokyo Japan).

Measurement of the levels of SVV in the cell culture supernatant. The transduced MSCs were plated in six-well plates (5,000 cells/cm²) overnight at 37°C in 5% CO₂. The medium
was then replaced with 2 ml/well DMEM/F12 for the HUMSCs and α-MEM for the DPSCs, followed by incubation for 48 h at 37°C in 5% CO₂. The supernatants were collected in order to confirm overexpression and secretion of SVV using a human enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions (Abcam, Cambridge, MA, USA). The cell number was determined for normalization.

Western blotting. To detect the overexpression of SVV in the HUMSCs and DPSCs, the proteins in the transduced cells were extracted using radioimmunoprecipitation assay lysis buffer supplemented with 1 mM phenylmethylsulfonyl fluoride (Beyotime Institute of Biotechnology, Haimen, China). The proteins were loaded onto 12% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% defatted milk [defatted milk powder (Quechao, Beijing, China) in tris-buffered saline supplemented with Tween20] for 1 h, the membranes were incubated with survivin (FL-142) rabbit polyclonal antibody raised against amino acids 1-142 of human survivin (1:100; sc-10811; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4°C.

DPSC transplantation. As been previous studies have examined the survival and differentiation of umbilical cord-derived MSCs in vivo (19), the current study focused on the properties of the DPSCs in vivo.

All experimental procedures involving animals were conducted under the approval of the Animal Care and Use Committee of Tongji University (Shanghai, China). Female C57BL/6 mice were housed at 22°C and 65% humidity with a 12 h light/dark cycle and access to food ad libitum.

The mice were randomly assigned to one of the following three groups: Control mice injected with PBS (n=6); mice transplanted with DPSCs (n=6) and mice transplanted with SVV-modified DPSCs (n=6). The adult 8-week-old mice were anesthetized using 0.5% pentobarbital sodium (Sigma-Aldrich). The heads of the mice were shaved and the skin was then placed directly over the striatum (coordinates: anterior/posterior, +2.0 mm; medial/lateral, +2.0 mm from the bregma). The control mice were anesthetized for 12 h light/dark cycle and access to food ad libitum.

In order to compare the gene expression profile between the control and the SVV-modified HUMSCs and DPSCs, RNA isolation was performed on the brains of the mice at x20 magnification. All the images were analyzed using ImageJ software (National Institutes of Health; Bethesda, MD, USA). Briefly, images of the transplanted cells were captured from five sections of each animal and the average intensity of the labels in each group was analyzed.

DNA sequencing and analysis. In order to compare the gene expression profile between the control and the SVV-modified HUMSCs and DPSCs, RNA isolation was performed on the cells using TRIzol® reagent (Invitrogen Life Technologies) and the total RNA was then digested with DNase I (Invitrogen Life Technologies) to ensure that the samples were not contaminated with genomic DNA. Duplicate experiments were performed for each sample. Library preparation and paired end sequencing (101 bp length) were performed using an Illumina HiSeq 2500 sequencer (Illumina, San Diego, CA, USA). Short reads were aligned to the reference human genome ( Homo sapiens GRCh37) using TopHat (20). The gene annotations were from the Ensembl database, packaged using iGenome (Illumina). The sequence reads were used to calculate the overall gene expression in terms of the reads per kilobase of exon per million mapped reads (RPKM). The differentially expressed transcripts were screened using the cufflinks procedure (21).

Abundant genes. Genes with an RPKM value >100 and levels of gene expression ≥2-fold higher than the control groups were identified in the HUMSCs, DPSCs and SVV-modified HUMSCs and DPSCs and functional enrichment analyses were performed using the Gene Ontology database (http://www.geneontology.org/GO.downloads. annotations.shtml) and the Kyoto Encyclopedia of Genes and Genomes pathway database (http://www.genome.jp/kegg/pathway.html).
Genes associated with stem cell differentiation. A total of five genes associated with stem cell differentiation, with RPKM values >5 in the control and SVV-modified HUMSCs and DPSCs, were selected based on the Gene Ontology database.

Cytokine-cytokine receptor interaction genes. A total of eight genes associated with cytokine-cytokine receptor interactions, with RPKM values >5 in the control and SVV-modified HUMSCs and DPSCs, were selected based on the Kyoto Encyclopedia of Genes and Genomes pathway database.

Data presentation and statistical analysis. Data are presented as the mean ± standard error of the mean (error bars). All significant differences were evaluated using Student's t-test or analysis of variance. Statistical analyses were performed using SPSS 15.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Phenotypic characterization of isolated HUMSCs and DPSCs. The shapes of the DPSCs were more similar to those of fibroblasts compared with the HUMSCs (Fig. 1A). Flow cytometric analysis revealed that the HUMSCs and DPSCs expressed a set of cluster of differentiation (CD) MSC markers (CD90, CD73 and CD105), however, they did not express endothelial/hematopoietic markers (CD34, CD45, CD11b or CD14, CD19, CD79α and HLA-DR. HUMSCs, human umbilical cord-derived mesenchymal stem cells; DPSCs, dental pulp-derived stem cells; FITC, fluorescein isothiocyanate; CD, cluster of differentiation.

Figure 1. Phenotypic characterization of HUMSCs and DPSCs. (A) Passage 5 DPSCs were more similar to fibroblasts than the HUMSCs. Scale bar: 500 µm. (B) 96.5% of the HUMSCs were positive for CD73, CD90 and CD105, but negative for CD34, CD45, CD11b or CD14, CD19, CD79α and HLA-DR. (C) 99.2% of the DPSCs were positive for CD73, CD90 and CD105, but negative for CD34, CD45, CD11b or CD14, CD19, CD79α and HLA-DR. HUMSCs, human umbilical cord-derived mesenchymal stem cells; DPSCs, dental pulp-derived stem cells; FITC, fluorescein isothiocyanate; CD, cluster of differentiation.

Figure 2. Adipogenic, osteogenic and chondrogenic differentiation of the (A-C) HUMSCs and (D-F) DPSCs, respectively. Lipid droplets, stained using oil red O, were present in the (A) HUMSCs, but not the (D) DPSCs (Scale bar: 250 µm). Osteogenic differentiation in the (B) HUMSCs and (E) DPSCs was detected using alizarin red S staining of calcium precipitation (Scale bar, 250 µm). Aggrecan, a chondrogenic marker, was highly expressed in the (C) HUMSCs and (F) DPSCs (Scale bar, 200 µm). HUMSCs, human umbilical cord-derived mesenchymal stem cells; DPSCs, dental pulp-derived stem cells.
droplets, stained using oil red O, were observed in the HUMSCs (Fig. 2A), but not the DPSCs (Fig. 2D). For osteo-
genic differentiation, the cells were cultured for 3 weeks in osteogenic media. Calcium precipitation, determined by alizarin red S staining, was observed in the HUMSCs and the DPSCs (Fig. 2B and E). The chondrogenic differentiation capacity of the HUMSCs and DPSCs were evaluated by examining the expression of aggrecan, a chondrogenic marker. Following culture with the HUMSCs and DPSCs in chondrogenic differentiation medium for 3 weeks, the cells exhibited increased expression of aggrecan (Fig. 2C and F).

**Efficiency of MSC transduction with lentiviral vectors containing SVV.** Following infection with the SVV recombinant lentivirus, overexpression of GFP was observed in the HUMSCs and DPSCs (Fig. 3). The efficiency of gene transduction was >90%.

**Protein expression of SVV.** The protein expression levels of SVV were determined by ELISA and western blotting. The protein levels of SVV were significantly increased in the cell culture supernatant of the SVV-modified HUMSCs and DPSCs compared with levels in the control groups (Fig. 4A). Furthermore, the secretion of SVV in the modified HUMSCs was significantly higher compared with that observed in the modified DPSCs. The western blotting revealed that modified HUMSCs and DPSCs exhibited a significant increase in the expression of SVV (Fig. 4B and C).
Control and SVV-modified DPSCs survive following intrastratal transplantation. In the present study, the survival and the expression of SVV in the control and SVV-modified DPSCs were investigated in vivo. The results demonstrated that the GFP signal, expressed by the inserted pLVX-IRES-ZsGreen1 vector, was marked in the control and SVV-modified cell lines 4 days after transplantation, however, it had weakened by day 14 (Fig. 5). In addition, the GFP signal in SVV-modified DPSCs was more marked compared with that in the control cells (Fig. 6). These results suggested that SVV promoted the
Figure 8. Immunohistochemical analysis of control and DP-SVV cells using GFAP. Microscopic images revealed a few GFP-labeled cells coexpressing GFAP (red) in the DP-SVV group 14 days after transplantation. Scale bar, 100 µm. DPSCs, dental pulp-derived stem cells; SVV, survivin; DP-SVV, SVV-modified DPSCs; GFAP, glial fibrillary acidic protein; PBS, phosphate-buffered saline; GFP, green fluorescent protein.

Figure 9. Heat map of group-specific highly expressed genes with RPKM values >100. (A) HUMSC-specific high expression genes. (B) HU-SVV-specific highly expressed genes. (C) DPSC-specific highly expressed genes. (D) DP-SVV-specific highly expressed genes. RPKM, reads per kilobase of exon per million mapped reads; HUMSCs, human umbilical cord-derived mesenchymal stem cells; DPSCs, dental pulp-derived stem cells; SVV, survivin; HU-SVV, SVV-modified HUMSCs; DP-SVV, SVV-modified DPSCs.
survival of the DPSCs in vivo. The expression of SVV in the transplanted SVV-modified DPSCs was higher than that in the control DPSCs on day 4. However, the expression of SVV in the transplanted DPSCs decreased 14 days after transplantation.

In addition, the present study examined the differentiation capacity of the control and SVV-modified DPSCs in vivo. Neither NeuN (a marker for neurons) nor glial fibrillary acidic protein (GFAP; a marker for astrocytes) were detected in the control or SVV-modified DPSCs 4 days after transplantation (Figs. 7 and 8). However, 14 days after transplantation, a few GFP-labeled cells coexpressed GFAP (Fig. 8), but not NeuN (Fig. 7) in the striatum.

Gene expression data analysis. The heat map of the abundant gene set is shown in Fig. 9. The genes with RPKM values >100 were analyzed with respect to each MSC group. A total of 16, 20, 58 and 22 genes were identified with RPKM values >100 and gene expression levels ≥2-fold higher in the HUMSCs, SVV-modified HUMSCs, DPSCs and SVV-modified DPSCs, respectively, compared with the control (Fig. 9). The most significant biological processes were ‘inflammatory response’, ‘vascular transport’, ‘platelet activation’ and ‘vascular transport’ for the HUMSCs, DPSCs, SVV-modified HUMSCs and SVV-modified DPSCs, respectively. The most significant pathways were ‘complement and coagulation cascades’, ‘hypoxia-inducible factor-1 signaling pathway’, ‘RNA polymerase’ and ‘SNARE interactions in vesicular transport’ for the HUMSCs, DPSCs, SVV-modified HUMSCs and SVV-modified DPSCs, respectively.

The expression of genes associated with biological activities among the groups was analyzed in order to clarify the molecular basis of the heterogeneity. Since MSCs possess multilineage differentiation potential, genes associated with stem cell differentiation were analyzed in the control and the SVV-modified HUMSCs and DPSCs. A total of 128 genes were identified as associated with stem cell differentiation in the four cell lines and genes with RPKM values >5 were selected. Analysis demonstrated higher expression levels of the FGF2 and MED10 stem cell differentiation genes in the SVV-modified HUMSCs, compared with the HUMSCs, DPSCs and SVV-modified DPSCs (Fig. 10A) and increased expression of FZD7 in the SVV-modified DPSCs compared with HUMSCs, HU-SVV and DPSCs. MSCs exhibit anti-inflammatory and immunomodulatory properties (22). Therefore, a comparative analysis of genes associated with cytokine-cytokine receptor interactions in the control and SVV-modified HUMSCs and DPSCs was also performed. A total of 196 genes associated with cytokine-cytokine receptor interactions were identified, from which genes with RPKM values >5 were selected. Clustering highlighted a group of genes with increased expression in the HUMSCs compared with HU-SVV, DPSCs and SVV-SVV, including tumor necrosis factor receptor superfamily (TNFRSF)6B, TNFRSF10D, LIF and vascular endothelial growth factor C (VEGFC; Fig. 10B). Clustering also highlighted a group of inflammatory-associated genes, the expression levels of which were highest in the SVV-modified DPSCs, including IL10RB, PLEKHO2, TNFRSF12A and VEGFC.

Discussion

MSCs may be isolated from a variety of sources, including bone marrow, umbilical cord, adipose tissue and dental pulp, and they may be used in several cell-based therapies and tissue engineering approaches. It is important to select the type of MSCs that are the most promising candidates for specific clinical applications. In the present study, the appearance of the DPSCs were more elongated compared with the HUMSCs. The surface antigens, CD90, CD73 and CD105, were used for the identification of HUMSCs and DPSCs, as these markers are indicated by the International Society for Cellular Therapy as positive markers for human MSCs (23). These MSCs lack expression of surface markers of endothelial or hematopoietic origin, including CD34, CD45, CD11b or CD14, CD19 or CD79a and HLA-DR.

In the present study, lipid droplets were observed in the HUMSCs rather than the DPSCs following the induction of adipogenic differentiation. Osteogenic differentiation was observed through calcium precipitation in the HUMSCs and DPSCs. The chondrogenic differentiation capacity of the

Figure 10. Heat map of genes associated with stem cell differentiation and cytokine-cytokine receptor interaction. (A) Genes associated with stem cell differentiation with RPKM values >5 were compared through RPKM value analysis in the HUMSCs, HU-SVV, DPSCs and DP-SVV cells. (B) Genes associated with cytokine-cytokine receptor interactions with RPKM values >5 in the four cell lines. RPKM, reads per kilobase of exon per million mapped reads; HUMSCs, human umbilical cord-derived mesenchymal stem cells; DPSCs, dental pulp-derived stem cells; SVV, survivin; HU-SVV, SVV-modified HUMSCs; DP-SVV, SVV-modified DPSCs; TNFRSF, tumor necrosis factor receptor superfamily; VEGF, vascular endothelial growth factor.
HUMSCs and DPSCs was also evaluated by examining the expression level of aggregan, which was marked in the two cell lines. These results indicated that the HUMSCs were more likely to differentiate into adipocytes compared with the DPSCs and that the two cell types are able to differentiate into osteoblasts and chondroblasts. These findings are consistent with those of Mangano et al (14) and Gronthos et al (24), which demonstrated that DPSCs can be induced to differentiate into osteoblasts, but not adipocytes.

Following transduction of the HUMSCs and DPSCs with a lentiviral vector, containing the full-length cDNA of survivin insertion, the expression of GFP indicated that the efficiency of gene transduction was >90%. The protein expression of SVV in the HUMSCs and DPSCs was compared using an ELISA assay and western blotting. The protein levels of SVV significantly increased in the SVV-modified HUMSCs and DPSCs compared with the controls. However, the expression of SVV in the cell culture supernatant was significantly higher in the SVV-modified HUMSCs compared with the SVV-modified DPSCs. Therefore, modified HUMSCs secreted more SVV protein compared with the modified DPSCs.

SVV is an important protein for cell death resistance and has been reported to modulate stem cell proliferation (25). As MSCs promote tissue repair by stimulating and modulating tissue-specific cells, SVV may enhance these stimulating and modulating effects of MSCs. A previous study on the differentiation of umbilical cord-derived MSCs in vivo (19), observed no neuronal or glial differentiation in the transplanted umbilical cord-derived MSCs. Therefore, the present study focused on the survival and differentiation of DPSCs in vivo. The results confirmed that SVV promoted the survival and astrocyte differentiation of the DPSCs in vivo.

The RNA sequencing analyses provided novel insight into the variable biological properties among the four groups. Higher levels of the expression of FGF2, which is involved in the development of the limb and nervous system, were observed in the SVV-modified HUMSCs and FZD7, which encodes receptors for Wnt signaling proteins, in the SVV-modified DPSCs. Genetic analyses elucidates the MSC-mediated anti-inflammatory and immunomodulatory properties of the different groups. The expression of IL10RB, an anti-inflammatory and immunoregulatory gene, was higher in the SVV-modified DPSCs than in the DPSCs, HUMSCs and SVV-modified HUMSCs. The expression levels of the TNFRSF6B and TNFRSF10D anti-inflammatory genes were higher in the HUMSCs than in the DPSCs or SVV-modified DPSCs and HUMSCs. Therefore, HUMSCs express higher levels of anti-inflammatory, immunoregulatory and stem cell differentiation-associated genes than DPSCs.

In conclusion, the source of MSCs and their subsequent modification can be selected according to the difference in differentiation, the effect of genetic modification and the molecular basis of the HUMSCs and DPSCs. However, further investigation is required in order to decide which cell line is most suitable for a specific clinical application.

Acknowledgements

This study was supported by grants from the Program of Shanghai Subject Chief Scientist (grant no. 2012XD1404400), the State Key Program of National Natural Science Foundation of China (grant no. 81330030), the Excellent Academic Leaders of Shanghai Health Field (grant no. XBR2013094), the National Science Foundation for Post-doctoral Scientists of China (grant no. 2012M520933), the Shanghai Municipal Health Bureau Youth Projects (grant no. 2012y4147) and the Fundamental Research Funds for the Central Universities (grant no. 2012KJ016).

References

1. Choong PF, Mok PL, Cheong SK, Leong CF and Then KY: Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy 9: 170-183, 2007.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells, Science 284: 143-147, 1999.
3. Xu R, Jiang X, Guo Z, Chen J, Zou Y, Ke Y, Zhang S, Li Z, Cai Y, Du M, Qian L, Tang Y and Zeng Y: Functional analysis of neuron-like cells differentiated from neural stem cells derived from bone marrow stroma cells in vitro. Cell Mol Neurobiol 28: 545-558, 2008.
4. Cui X, Chen L, Ren Y, Ji Y, Liu W, Liu J, Yan Q, Cheng L and Sun YE. Genetic modification of mesenchymal stem cells in spinal cord injury repair strategies. Biosci Trends 7: 202-208, 2013.
5. Kode JA, Mukherjee S, Joglekar MV and Hardikar AA: Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 11: 377-391, 2009.
6. Meirelles Lda S, Fontes AM, Covas DT and Caplan AI: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20: 419-427, 2009.
7. Davies OG, Smith AJ, Cooper PR, Shelton RM and Scheven BA: The effects of cryopreservation on cells isolated from adipose, bone marrow and dental pulp tissues. Cryobiology 69: 342-347, 2014.
8. Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC and Christopherson KW II: Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Transfusion 48: 2638-2644, 2008.
9. Moretti P, Hatlapatka T, Marten D, Lavrentieva A, Majoire I, Hass R and Kasper C: Mesenchymal stem cells derived from human umbilical cord tissue: primitive cells with potential for clinical and tissue engineering applications. Adv Biochem Eng Biotechnol 123: 29-54, 2010.
10. Lisianyi MI: Mesenchymal stem cells and their immunological properties. Fiziol Zh 59: 126-134, 2013 (In Ukrainian).
11. Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, Lee JE, Kim YJ, Yang SK, Jung HL, et al: Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 259: 150-156, 2009.
12. Yang CC, Shih YH, Ko MH, Hsu SY, Cheng H and Fu YS: Transplantation of human umbilical mesenchymal stem cells from Wharton's jelly after complete transection of the rat spinal cord. PLoS One 3: e3336, 2008.
13. Ma H, Wu Y, Xu Y, Sun L and Zhang X: Human umbilical mesenchymal stem cells attenuate the progression of focal segmental glomerulosclerosis. Am J Med Sci 346: 486-493, 2013.
14. Gronthos S, Mankani M, Brahim J, Robey PG and Shi S: Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 97: 13625-13630, 2000.
15. Zhao Y, Wang L, Jin Y and Shi S: Fas ligand regulates the immunomodulatory properties of dental pulp stem cells. J Dent Res 91: 948-954, 2012.
16. Kermari AJ, Fathi F and Mowla SJ: Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: potential application in cell-based gene therapy. Rejuvenation Res 11: 379-386, 2008.
17. Bhowmick R and Girotti AW: Cytotoxic signaling associated with nitric oxide upregulation in tumor cells subjected to photodynamic therapy-like oxidative stress. Free Radic Biol Med 57: 39-48, 2013.
18. Kikuchi-Taura A, Taguchi A, Kanda T, Inoue T, Kasahara Y, Hirose H, Sato I, Matsuyama T, Nakagomi T, Yamahara K, et al: Human umbilical cord provides a significant source of unexpanded mesenchymal stromal cells. Cytotherapy 14: 441-450, 2012.

19. Fink KD, Rossignol J, Crane AT, Davis KK, Bombard MC, Bavar AM, Clerc S, Lowrance SA, Song C, Lescaudron L and Dunbar GL: Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis. Stem Cell Res Ther 4: 130, 2013.

20. Trapnell C, Pachter L and Salzberg SL: TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105-1111, 2009.

21. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7: 562-578, 2012.

22. Baron F and Storb R: Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol Blood Marrow Transplant 18: 822-840, 2012.

23. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8: 315-317, 2006.

24. Mangano C, De Rosa A, Desiderio V, d’Aquino R, Piattelli A, De Francesco F, Tirino V, Mangano F and Papaccio G: The osteoblastic differentiation of dental pulp stem cells and bone formation on different titanium surface textures. Biomaterials 31: 3543-3551, 2010.

25. Fukuda S, Foster RG, Porter SB and Pelus LM: The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100: 2463-2471, 2002.